Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Endostar continuous intravenous infusion combined with S-1 and oxaliplatin chemotherapy could be effective in treating liver metastasis from gastric cancer.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • المؤلفون: Yang H;Yang H; Sui Y; Sui Y; Guo X; Guo X; Tan X; Tan X; Li Y; Li Y; Wang M; Wang M
  • المصدر:
    Journal of cancer research and therapeutics [J Cancer Res Ther] 2018 Dec; Vol. 14 (Supplement), pp. S1148-S1151.
  • نوع النشر :
    Comparative Study; Journal Article; Randomized Controlled Trial
  • اللغة:
    English
  • معلومة اضافية
    • المصدر:
      Publisher: Medknow Publications Country of Publication: India NLM ID: 101249598 Publication Model: Print Cited Medium: Internet ISSN: 1998-4138 (Electronic) Linking ISSN: 19984138 NLM ISO Abbreviation: J Cancer Res Ther Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: Mumbai, India : Medknow Publications
    • الموضوع:
      Antineoplastic Combined Chemotherapy Protocols/*therapeutic use ; Endostatins/*therapeutic use ; Liver Neoplasms/*drug therapy ; Oxaliplatin/*therapeutic use ; Oxonic Acid/*therapeutic use ; Recombinant Proteins/*therapeutic use ; Stomach Neoplasms/*pathology ; Tegafur/*therapeutic use; Adult ; Aged ; Angiogenesis Inhibitors/therapeutic use ; Disease-Free Survival ; Drug Combinations ; Female ; Humans ; Infusions, Intravenous/methods ; Liver Neoplasms/secondary ; Male ; Middle Aged ; Neoplasm Staging ; Treatment Outcome
    • نبذة مختصرة :
      Objective: Endostar is a new vascular epithelial inhibitor, which is reported to be effective in treating liver metastasis from gastric cancer. However, the optimal therapeutic regimen of Endostar remains unclear. Thus, our study aimed to examine the efficacy and safety of Endostar continuous intravenous infusion combined with S-1 and oxaliplatin (SOX) chemotherapy in treating such patients.
      Patients and Methods: A total of sixty patients with liver metastasis from gastric cancer admitted in our department were enrolled. The experimental group (n = 30) was treated with Endostar continuous intravenous infusion combined with SOX regimen chemotherapy, and the control group (n = 30) received SOX regimen chemotherapy alone. All patients received at least two cycles of treatment. The objective effective rate (ORR), disease control rate (DCR), progression-free survival (PFS), and adverse reactions were recorded and compared.
      Results: The ORR of the experimental group and control group was 63.3% and 43.3% (P = 0.046), respectively. The DCR of the experimental group and the control group was 86.7% and 73.3% (P = 0.034). The median PFS in the experimental group was longer than that in the control group (15.3 months vs. 12 months). There was no significant difference in the incidence of common adverse reactions such as gastrointestinal reaction, bone marrow suppression, and cardiac toxicity between the two groups. No death was observed in the study period.
      Conclusion: Continuous infusion of Endostar combined with SOX chemotherapy could be recommended for the treatment of liver metastasis from gastric cancer due to its high effective rate, and Endostar did not increase the incidence of adverse reactions.
      Competing Interests: None
    • Contributed Indexing:
      Keywords: Efficacy; Endostar; gastric cancer; liver hepatic metastasis; safety
    • الرقم المعرف:
      0 (Angiogenesis Inhibitors)
      0 (Drug Combinations)
      0 (Endostatins)
      0 (Recombinant Proteins)
      04ZR38536J (Oxaliplatin)
      150863-82-4 (S 1 (combination))
      1548R74NSZ (Tegafur)
      5VT6420TIG (Oxonic Acid)
      GVG18ZDN65 (endostar protein)
    • الموضوع:
      Date Created: 20181213 Date Completed: 20190306 Latest Revision: 20220408
    • الموضوع:
      20221213
    • الرقم المعرف:
      10.4103/0973-1482.204880
    • الرقم المعرف:
      30539861